Novartis is set to unveil data from 60 company- and investigator-sponsored abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress. These presentations spotlight advances that could reshape clinical practice across both solid tumors and hematologic conditions.
“Our broad oncology and hematology portfolio—led by Kisqali, Pluvicto, Scemblix, and Fabhalta—underscores our leadership and innovation in the field,” said Dr. Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis. “At ASCO and EHA, we will share new insights on these key therapies, updates from our pipeline, and progress in radioligand therapy research.”
Novartis will also highlight strategic U.S. partnerships with the NFL, Alliance for Breast Cancer Policy, and ZERO Prostate Cancer. These collaborations aim to promote proactive health decisions and support policies focused on improving patient outcomes.
“As the cancer landscape shifts—with diagnoses occurring earlier and older patients living longer—our responsibility extends beyond developing new treatments,” said Victor Bultó, President, US, Novartis. “We are working across the healthcare ecosystem to foster early detection and respond to the evolving needs of today’s cancer patients.”
Key ASCO 2025 Highlights
Kisqali® (ribociclib)
- Efficacy across menopausal status and age in NATALEE trial (Abstract #516) – Rapid Oral, June 1
- Real-world analysis in Black patients with HR+/HER2− early breast cancer (Abstract #527) – Poster, June 2
- Adjuvant WIDER trial in a clinical-practice-like population (Abstract #TPS617) – Poster, June 2
- First-line ribociclib vs chemotherapy in advanced HR+/HER2− breast cancer with/without liver metastases (Abstract #1069) – Poster, June 2
Scemblix® (asciminib)
- Phase 2 ASC2ESCALATE in CML-CP post-TKI (Abstract #6516) – Rapid Oral, May 30
- ASC4START trial: Scemblix vs nilotinib in newly diagnosed CML-CP (Abstract #6501) – Oral, June 2
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)
- Real-world data on early vs delayed treatment in mCRPC (Abstracts #e17030, #e17035) – Online
- PSMA-delay castration study in oligometastatic prostate cancer (Abstract #TPS5127) – Poster, June 2
Key EHA 2025 Highlights
Fabhalta® (iptacopan)
- APPULSE-PNH trial: Iptacopan monotherapy shows hemoglobin improvement in PNH patients (Abstract #S183) – Oral, June 13
- Long-term safety and efficacy from extension studies (Abstract #PF660) – Poster, June 13
Scemblix® (asciminib)
- ASC4START trial: Superior tolerability vs nilotinib in CML-CP (Abstract #S166) – Oral, June 13
- Patient-reported outcomes in ASC4FIRST trial (Abstract #PS1588) – Poster, June 14
- ASC2ESCALATE interim analysis supports use post-first TKI (Abstract #PF595) – Poster, June 13
Pelabresib (DAK539)
- MANIFEST-2 study: Long-term outcomes in myelofibrosis patients (Abstract #S223) – Oral, June 12
Ianalumab (VAY736)
- VAYHIT3 study: Phase 2 results in primary immune thrombocytopenia (Abstract #S312) – Oral, June 15
Rapcabtagene Autoleucel (YTB323)
- Updated data in relapsed/refractory diffuse large B-cell lymphoma (Abstract #PF1152) – Poster, June 13
A Vision for the Future of Cancer Care
For over 30 years, Novartis has been dedicated to transforming cancer treatment through innovation, research, and partnerships. With more than 35 R&D programs spanning solid tumors, hematology, and radioligand therapy, Novartis continues to lead in developing targeted, patient-centered cancer therapies. The company’s work also extends to advocacy, education, and early diagnosis to ensure comprehensive support for people facing cancer.
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
